Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells


Online Interview with Guest Editor of JCMT Prof. Steven N. Fiering

Published on: 26 Aug 2022 Viewed: 423

On August 24, 2022, the Editorial Office of Journal of Cancer Metastasis and Treatment(JCMT) was very honored to interview Prof. Steven N. Fiering who is from Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, United States. He is the Guest Editor of the Special Issue entitle “Role of Immune Cells in the Tumor Microenvironment”.

It is a great honor that we have successively invited Prof. Steven N. Fiering to participate in our journal and have organized excellent special issues. As an outstanding professor in microbiology and immunology, he also has been invited by authoritative program to do an online interview on immune system. In this interview with JCMT, Prof. Steven N. Fiering shared with us his resent research results, personal experiences with tricking the immune system into fighting back and professional insights about emerging potential in anticancer immunotherapies.

Let us take a look at what Prof. Fiering has said:

Q1: In 2021, you organized the special issue entitled “Role of Immune Cells in the Tumor Microenvironment” on JCMT. The Special Issue mainly focused on the immune cells and the most viewed paper is “B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma”.  So after more than a year, are there any new developments in this regard you would like to share with us?

Q2: You recently published an article titled “Emerging Potential of Plant Virus Nanoparticles (PVNPs) in Anticancer Immunotherapies”. What do you think of the current situation and future development of emerging potential in anticancer immunotherapies?

Q3: It is well known that you have been invited by Finding Genius Podcast with online interview“Characterizing Cancer: How Steven N. Fiering Approaches Cancer Therapy Treatment” which mainly focused on helping define cancer by its interaction with the immune system and use of the body's natural signals and systems. Could you describe how to find ways to trick the immune system into fighting back to our audiences?

Q4: As an outstanding Professor of Microbiology and Immunology, what is your motivation of researching in this field? What advice could you give to younger researchers in how to write a high quality of paper in this field?

Biography of the Interviewee

Prof. Steven N. Fiering
Steven Fiering is a professor of Microbiology and Immunology at Dartmouth Geisel School of Medicine. Dr. Fiering received his Bachelor of Science from the University of Michigan in 1975, and his Doctorate from Stanford in 1990.

After postdoctoral work as an NIH and Burroughs-Wellcome Foundation supported research fellow at the Fred Hutchinson Cancer Research Center, Dr. Fiering joined the faculty of the Department of Microbiology at Dartmouth Medical School in 1997. Prof. Fiering's research interests are in cancer immunology and immunotherapy. His current focus is on understanding and optizing “in situ vaccination”, localized tumor treatment that stimulates local antitumor immunity in the treated tumor which generates systemic antitumor immunity against untreated metastatic tumors (abscopal effect). The primary in situ vaccination approach his lab is working with currently is cowpea mosaic virus, a plant virus that does not infect mammalian cells but does strongly activate multiple toll-like receptors and activates the antitumor immune response.

Thank you for reading and following along. Please also pay more attention to forthcoming articles by Prof. Fiering.

Respectfully Submitted by the Journal Editorial Office
Journal of Cancer Metastasis and Treatment

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties